Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK112 + nab-paclitaxel + paclitaxel
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**AK112 + nab-paclitaxel + paclitaxel** is an experimental multi-agent combination therapy under clinical investigation for breast cancer, particularly triple-negative breast cancer (TNBC). - **AK112** is a humanized IgG1 monoclonal antibody targeting the PD-1 immune checkpoint protein, functioning as an immune checkpoint inhibitor. - **nab-paclitaxel** (brand name Abraxane) is a nanoparticle albumin-bound formulation of paclitaxel, a microtubule inhibitor; this formulation facilitates enhanced delivery to tumors and a distinct toxicity profile compared to conventional paclitaxel. - **paclitaxel** is a classic microtubule-stabilizing agent, widely used as a chemotherapeutic cytotoxic drug. This combination is being studied in the neoadjuvant setting for increasing pathological complete response rates in early or locally advanced TNBC patients[1][3].
- Other names
- albumin-bound paclitaxel
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on AK112 + nab-paclitaxel + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK112 + nab-paclitaxel + paclitaxel.